Company Of The Day: Johnson & Johnson
What?
Johnson & Johnson (NYSE:JNJ) is negotiating partnership deals with two unnamed Chinese companies, per a report from the Financial Times.
So What?
- What’s Next For Johnson & Johnson Stock After Beating Q1 Earnings?
- Here’s What To Expect From Johnson & Johnson’s Q1
- What’s Next For Johnson & Johnson Stock After A 6% Decline In A Month?
- Is Johnson & Johnson Stock A Better Pick Over AbbVie?
- Will Johnson & Johnson Stock Rebound To Its Pre-Inflation Shock Highs of $185?
- Should You Pick Johnson & Johnson Stock At $160?
U.S. pharma companies have been increasingly interested in licensing drugs from Chinese biotech players, who are seeing a lot of innovation, driven by higher public and private investments. Moreover, J&J’s past experience with Chinese collaborations has been good. Last week, the U.S. FDA approved Carvykti, a cancer drug that J&J developed along with China’s Legend Biotech.
See Our Complete Analysis For Johnson & Johnson
What if you’re looking for a more balanced portfolio instead? Here’s a high-quality portfolio that’s beaten the market consistently since the end of 2016.
| Returns | Mar 2022 MTD [1] |
2022 YTD [1] |
2017-22 Total [2] |
| JNJ Return | 5% | 1% | 49% |
| S&P 500 Return | -4% | -12% | 88% |
| Trefis MS Portfolio Return | -5% | -15% | 236% |
[1] Month-to-date and year-to-date as of 3/8/2022
[2] Cumulative total returns since the end of 2016